$The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer$

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer

Background. Thirty to forty percent of patients with high grade nonmuscle invasive bladder cancer (NMIBC) fail to respond to intravesical therapy with bacillus Calmette-Guerin (BCG). Interferon-α2B plus BCG has been shown to be effective in a subset of patients with NMIBC BCG refractory disease. Her...

Full description

Bibliographic Details
Main Authors:	Andres F. Correa, Katherine Theisen, Matthew Ferroni, Jodi K. Maranchie, Ronald Hrebinko, Benjamin J. Davies, Jeffrey R. Gingrich
Format:	Article
Language:	English
Published:	Hindawi Limited 2015-01-01
Series:	Advances in Urology
Online Access:	http://dx.doi.org/10.1155/2015/656918

Similar Items

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients
by: Mark Kowalski, et al.
Published: (2010-11-01)

Advances in nonmuscle invasive bladder cancer
by: Badrinath R Konety
Published: (2015-01-01)

A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer
by: Julie Mariam Joshua, et al.
Published: (2019-03-01)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
by: Jan-Friedrich Jokisch, et al.
Published: (2015-01-01)

Active surveillance for nonmuscle invasive bladder cancer
by: Makito Miyake, et al.
Published: (2016-06-01)

Diagnostics techniques in nonmuscle invasive bladder cancer
by: Ayman Soubra, et al.
Published: (2015-01-01)

Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder
by: Savino M. Di Stasi, et al.
Published: (2015-12-01)

Best practice in the treatment of nonmuscle invasive bladder cancer
by: Anastasios Anastasiadis, et al.
Published: (2012-02-01)

Nonmuscle invasive bladder cancer: a primer on immunotherapy
by: Mahir Maruf, et al.
Published: (2016-06-01)

New therapies in nonmuscle invasive bladder cancer treatment
by: Kareem N Rayn, et al.
Published: (2018-01-01)

Adjuvant intravesical chemotherapy with titanium glycerosolvate aquacomplex versus BCG therapy in patients with high risk nonmuscle-invasive bladder cancer
by: A. V. Zamyatin, et al.
Published: (2020-11-01)

Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma of the bladder
by: Michael S. Cookson, et al.
Published: (2014-10-01)

Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
by: A.P.M. van der Meijden
Published: (2006-01-01)

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy
by: Yasuyoshi Miyata, et al.
Published: (2015-01-01)

Current Status of Radical Cystectomy on High-risk Nonmuscle Invasive Bladder Cancer
by: DENG Kangli, et al.
Published: (2021-05-01)

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer
by: Marian S. Wettstein, et al.
Published: (2015-01-01)

Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study
by: Vincenzo Pagliarulo, et al.
Published: (2015-12-01)

Diminished efficacy of bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer
by: D Margel, et al.
Published: (2011-10-01)

Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer
by: Shingo Tsuji, et al.
Published: (2016-01-01)

Small cell bladder cancer: should we consider prophylactic cranial irradiation?
by: Tara Nikonow Morgan, et al.

MicroRNA-21 could be a molecular marker to predict the recurrence of nonmuscle invasive bladder cancer
by: Nilay Mitash, et al.
Published: (2017-01-01)

A Urinary Drug-Disposing Approach as an Alternative to Intravesical Chemotherapy for Treating Nonmuscle Invasive Bladder Cancer
by: Bellat, V., et al.
Published: (2022)

Assessment of Pain Management, Acceptance of Illness, and Adjustment to Life with Cancer in Patients with Nonmuscle Invasive Bladder Cancer
by: Wojciech Krajewski, et al.
Published: (2018-01-01)

Clinical Implications and Prognostic Values of Prostate Cancer Susceptibility Candidate Methylation in Primary Nonmuscle Invasive Bladder Cancer
by: Young-Won Kim, et al.
Published: (2015-01-01)

NONMUSCLE INVASIVE TRANSITIONAL CELL CARCINOMA OF URINARY BLADDER – ADJUVANT INTRAVESICAL THERAPIES AFTER TRANSURETHRAL TUMOR RESECTION
by: Nicolae Grigore, et al.
Published: (2017-09-01)

Can tumor recurrence be reduced with plasma-kinetic vaporization of the area around the tumor in nonmuscle invasive bladder cancer?
by: Yüksel Yılmaz, et al.
Published: (2018-07-01)

The results of treatments and complications of immunotherapy (BCG and alpha-interferon) in superficial TCC of bladder
by: Jabalameli P, et al.
Published: (1994-04-01)

The comparative study of the effectiveness of BCG and Alfa-Interferon in preventing the recurrence of bladder tumor
by: Ghazimoghadam B (MD), et al.
Published: (1999-05-01)

INTRAVESICAL BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
by: K. M. Figurin
Published: (2014-07-01)

INTRAVESICAL BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
by: K. M. Figurin
Published: (2014-07-01)

Long-term results of adjuvant intravesical chemotherapy with titanium glycerosolvate aquacomplex in patients with high risk nonmuscle-invasive bladder cancer
by: A. V. Zamyatin, et al.
Published: (2019-04-01)

Safety, feasibility, and quality of holmium laser en-bloc resection of nonmuscle invasive bladder tumors – A single-center experience
by: Pankaj N Maheshwari, et al.
Published: (2020-01-01)

Alternative Therapies to Bacillus Calmette-Guérin Shortage for Nonmuscle Invasive Bladder Cancer in Brazil and Other Underdeveloped Countries: Management Considerations
by: Marcelo Langer Wroclawski, et al.
Published: (2019-08-01)

Editorial comment on “Maintenance bacillus Calmette-Guérin therapy for nonmuscle-invasive bladder cancer: A need for more randomized trials”
by: Shu-Pin Huang
Published: (2015-06-01)

S100A16 regulated by Snail promotes the chemoresistance of nonmuscle invasive bladder cancer through the AKT/Bcl-2 pathway
by: Wang C, et al.
Published: (2019-03-01)

The value of extensive transurethral resection in the diagnosis and treatment of nonmuscle invasive bladder cancer with respect to recurrence at the first follow-up cystoscopy
by: Qie Y, et al.
Published: (2016-04-01)

INTRAVESICULAR IMMUNOTHERAPY WITH BCG VACCINE AND INTERFERON-αα2B FOR NON-INVASIVE CARCINOMA OF THE URINARY BLADDER: RESULTS OF PROSPECTIVE RANDOMIZED STUDY
by: A. A. Minich, et al.
Published: (2014-07-01)

INTRAVESICULAR IMMUNOTHERAPY WITH BCG VACCINE AND INTERFERON-αα2B FOR NON-INVASIVE CARCINOMA OF THE URINARY BLADDER: RESULTS OF PROSPECTIVE RANDOMIZED STUDY
by: A. A. Minich, et al.
Published: (2014-07-01)

Comparison of sterile water irrigation versus intravesical mitomycin C in preventing recurrence of nonmuscle invasive bladder cancer after transurethral resection
by: Priyank Bijalwan, et al.
Published: (2017-01-01)

Safety and efficacy of en bloc transurethral resection versus conventional transurethral resection for primary nonmuscle-invasive bladder cancer: a meta-analysis
by: Dong Zhang, et al.
Published: (2020-01-01)

Cannot write session to /tmp/vufind_sessions/sess_suoktr685h95m31kmbmj83j29p